| | |

Medical Marijuana No Longer Tabu Among Mesothelioma Doctors

A new survey suggests that medical marijuana is gaining acceptance among doctors who treat malignant mesothelioma and other types of cancer, opening the door for more patients to explore its potential to manage their disease.

The survey of 400 oncologists conducted by the American Society of Clinical Oncology found that as many as 80 percent of the 237 respondents have discussed medical marijuana with their patients. The survey found this was usually because a patient brought it up.

Unfortunately for mesothelioma patients, the survey also revealed that fewer than one in three doctors felt knowledgeable enough about medical marijuana to make a recommendation.

“We need to bridge this gap so oncologists have the unbiased information they need to assist with decision-making related to medical marijuana use,” said study author Ilana Braun, MD, of the Dana-Farber Cancer Institute in a news release.

Key Findings from Marijuana Doctor Survey

The good news to come out of the survey for people facing a mesothelioma diagnosis is that, if they are interested in integrating medical marijuana into their treatment, they are more likely to find that their doctor is open to the idea, especially if they live in a Western state where medical marijuana is legal.

Nearly half (46%) of the survey respondents say they had recommended medical marijuana to cancer patients within the past year.

 

The survey also revealed that:

  • More than two-thirds of oncologists believed medical marijuana to be helpful in alleviating pain
  • Most doctors view medical marijuana to be less risky that opioids
  • Nearly two-thirds (65%) viewed medical marijuana as good as or better than standard treatments for poor appetite and weight loss
  • Hospital-based oncologists were less likely to recommend medical marijuana than those practicing independently

Patients Stories of Marijuana in Cancer

Like other medicinal plants, marijuana contains hundreds of active ingredients, any combination of which may play a role in fighting intractable cancers like malignant mesothelioma.

Although there have been no studies of whole-plant marijuana in mesothelioma treatment, a number of studies have been conducted on cancer and cannabinoids, products derived from one or two of the active ingredients (typically CBD and THC) in the marijuana plant.

Meanwhile, the anecdotal evidence about the plant and/or its constituents continues to mount among patients with malignant mesothelioma and similar cancers.

Just this week, the UK news site Express reports the case of a lung cancer patient who claims to have significantly reduced the size of his tumor using cannabidiol (CBD oil), a type of cannabinoid.

According to the article, 83-year-old Gary Hill of Staffordshire was diagnosed with lung cancer almost two years ago, at which time his oncologist predicted that he would not survive more than a year without standard cancer treatment.

After using three to nine drops of CBD oil under his tongue several times a day over the course of a month, Hill says a radiology report showed “near total resolution” of a mass in his left lung and his lymph nodes had shrunk to normal size.

More Studies Are Needed

Despite the growing number of stories like Hill’s, and the fact that the American Cancer Society acknowledges: “Certain cannabinoids may slow growth and reduce spread of some forms of cancer”, the US Drug Enforcement Administration still lists marijuana and its cannabinoids as Schedule I controlled substances.

Leaders at ASCO say it is time for that to change.

“It’s clear from this study that patients and their families want to know more about medical marijuana for the treatment of cancer-related symptoms, and often initiate discussions with their oncologists,” concludes Andrew Epstein, MD, ASCO’s patient care expert. “This study highlights the important need for more research on the use of medical marijuana in oncology, so we can provide informed guidance and care that meets all of our patients’ needs.”

Sources:

“Most oncologists have discussed medical marijuana with patients”, May 10, 2018, American Society of Clinical Oncology news release, EurekAlert

Atherton, Matt, “Lung cancer patient SHRUNK tumour ‘using cannabidiol CBD oil’”, June 11, 2018, Express website

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • |

    Chemical in Wine May Improve Mesothelioma Treatment

    There’s new evidence that a compound found in red wine may help improve the effectiveness of chemotherapy treatment for malignant pleural mesothelioma. Last year, a team of Korean researchers released the world’s first study on the mesothelioma-fighting power of resveratrol, a natural phenol derived from the skin of red grapes and found in red wine and grape juice. Now, the same team says resveratrol also appears to enhance the chemosensitivity of malignant mesothelioma cells. Study author Yoon-Jin Lee and colleagues discovered  a synergistic cancer-fighting effect in mesothelioma cells treated with both resveratrol and clofarabine, a prescription drug often used to treat acute lymphoblastic leukemia. Together, resveratrol and clofarabine “induced a strong cytotoxic effect” by influencing levels of the tumor suppressor,…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…

  • | |

    Mesothelioma Study Finds New Treatment Target

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…